U.S. News

Woman who died after getting AstraZeneca vaccine had ‘unusual symptoms’: report

A 60-year-old Danish lady who acquired the AstraZeneca COVID-19 vaccine had “highly unusual symptoms” earlier than dying of a blood clot, in line with a report.

The lady had a low variety of blood platelets and clots in small and huge vessels, Reuters reported, citing the Danish Medicines Agency.

The company cited just a few related instances reported in Norway and within the European Medicines Agency database of drug unwanted side effects, in line with the information outlet.

“It was an unusual course of illness around the death that made the Danish Medicines Agency react,” it mentioned in an announcement Sunday night time.

On Saturday, Norway mentioned three individuals — all beneath age 50 — who had acquired the jab had been being handled in a hospital for bleeding, blood clots and a low rely of blood platelets, which well being officers labeled “unusual symptoms.”

Denmark, Norway and Iceland mentioned final week they might halt the introduction of the AstraZeneca shot.

Norway mentioned three individuals who had acquired the AstraZeneca shot had been being handled in a hospital for bleeding, and blood clots.
REMKO DE WAAL/ANP/AFP by way of Getty Images

European vaccination applications have been rocked by latest experiences that recipients of the AstraZeneca inoculation have suffered blood clots.

AstraZeneca tried to quell safety concerns after blood clots emerged in some people who received their COVID-19 vaccine.
AstraZeneca tried to quell security issues after blood clots emerged in some individuals who acquired their COVID-19 vaccine.
Chris Jackson/Getty Images

The European Medicines Agency has mentioned there isn’t a indication that the instances had been associated to the vaccination, a view that was echoed by the World Health Organization on Friday.

AstraZeneca tried to quell security issues after blood clots emerged in some individuals, prompting a few dozen nations to cease utilizing some or all of their doses.

The British drugmaker’s evaluate of security knowledge from greater than 17 million individuals who acquired the shot within the UK and the European Union discovered no proof of a better threat for pulmonary embolism or deep vein thrombosis, situations related to clots, it mentioned in a Sunday statement.

There had been additionally no indicators of a better threat for thrombocytopenia, or a low rely of blood platelets, in line with AstraZeneca.

Back to top button